The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
Abstract
PURPOSE: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). PATIENTS AND METHODS: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. RESULTS: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. CONCLUSION: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age > or = 40 years at the time of transplant and who received TBI are at greatest risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Report of the Committee on Hodgkin's Disease Staging Classification.
Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. W., & Tubiana, M. (1971) · PubMed · Cited by 4,166
Risk of Second Cancers after Treatment for Hodgkin's Disease
Tucker, M. A., Coleman, C. N., Cox, R. S., Varghese, A., & Rosenberg, S. A. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801143180203 · Cited by 718
Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia
Pui, C.-H., Ribeiro, R. C., Hancock, M. L., Rivera, G. K., Evans, W. E., Raimondi, S. C., Head, D. R., Behm, F. G., Mahmoud, M. H., Sandlund, J. T., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112123252402 · Cited by 713
Pepe, M. S., & Mori, M. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120803 · Cited by 620
Leukemia Following Hodgkin's Disease
Kaldor, J. M., Day, N. E., Clarke, E. A., Van Leeuwen, F. E., Henry-Amar, M., Fiorentino, M. V., Bell, J., Pedersen, D., Band, P., Assouline, D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220102 · Cited by 485
Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast Cancer
Curtis, R. E., Boice, J. D., Stovall, M., Bernstein, L., Greenberg, R. S., Flannery, J. T., Schwartz, A. G., Weyer, P., Moloney, W. C., & Hoover, R. N. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262605 · Cited by 446
Pedersen-Bjergaard, J., Daugaard, G., Hansen, S. W., Rørth, M., Philip, P., & Larsen, S. O. (1991) · The Lancet · doi:10.1016/0140-6736(91)90490-g · Cited by 362
Leukemia After Therapy With Alkylating Agents for Childhood Cancer2
Tucker, M. A., Meadows, A. T., Boice, J. D., Stovall, M., Oberlin, O., Stone, B. J., Birch, J., Voûte, P. A., Hoover, R. N., Fraumeni, J. F., et al. (1987) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/78.3.459 · Cited by 352
Cited by
Krishnan, A., Bhatia, S., Slovak, M. L., Arber, D. A., Niland, J. C., Nademanee, A., Fung, H., Bhatia, R., Kashyap, A., Molina, A., et al. (2000) · Blood · doi:10.1182/blood.v95.5.1588.005k38_1588_1593 · Cited by 285
Metadata
- Authors
- Darrington, D. L., Vose, J. M., Anderson, J. R., Bierman, P. J., Bishop, M. R., Chan, W. C., Morris, M. E., Reed, E. C., Sanger, W. G., & Tarantolo, S. R.
- Venue
- Journal of Clinical Oncology
- Published
- 1994-12
- Volume
- 12
- Issue
- 12
- Pages
- 2527-2534
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1877303819
- Cited by
- 332
- References
- 20
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. https://app.cochat.ai/papers/10.1200/jco.1994.12.12.2527
- The paper
- Darrington, D. L., Vose, J. M., Anderson, J. R., Bierman, P. J., Bishop, M. R., Chan, W. C., Morris, M. E., Reed, E. C., Sanger, W. G., & Tarantolo, S. R. (1994). Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1994.12.12.2527
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
